← Procter & Gamble overview

Procter & Gamble vs Kimberly-Clark: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Procter & Gamble Company (PG)

Q3 2026
▲2▼2

P&G hit by tariffs and weak sales, but cuts costs and expands wellness

  • Tariff and commodity headwinds P&G expects tariffs and higher raw material costs to reduce full-year profit by about $1 billion, or $0.56 per share, putting pressure on earnings.

    This is a major new financial headwind that directly impacts profitability.

  • Weak Q4 results and cautious guidance Q4 revenue missed estimates and net income fell to $3.04 billion from $3.62 billion. Fiscal 2027 guidance points to slower organic sales growth of 1–3%.

    This shows recent underperformance and a dimmer outlook, key drivers of investor sentiment.

  • Cost cuts and shareholder returns P&G is cutting 7,000 jobs and returning over $15 billion to shareholders, with a 2.9% dividend yield and a 70-year dividend streak.

    These actions aim to boost efficiency and reward shareholders, supporting the stock.

  • Wellness acquisition and beauty growth P&G agreed to buy Thorne for $3.8 billion to expand into wellness, while its beauty segment grew 11%, signaling strength in premium categories.

    This highlights strategic growth initiatives that could offset weaknesses elsewhere.

August 2026
▲3▼1

P&G buys Thorne for wellness push, but volumes stay flat

  • P&G buys Thorne for $3.8 billion P&G agreed to buy supplement maker Thorne for $3.8 billion in cash, expanding into vitamins and wellness. This gives P&G a faster-growing category and a way to reach younger shoppers, which supports the stock by adding a new source of future sales.

    The Thorne acquisition is the period's biggest new event and directly shapes P&G's growth story.

  • Beauty segment grows 11%, dividend streak hits 70 years P&G's beauty unit posted 11% sales growth and 7% organic growth on higher volumes, while the company extended its dividend increase streak to 70 years with $10 billion planned payouts. Strong beauty results and steady dividends make the stock more attractive to long-term holders.

    This shows which part of P&G is actually growing and reinforces the income appeal that supports the share price.

  • Analysts say P&G stock looks undervalued After the Thorne deal, valuation work put P&G's intrinsic value near $201 a share, about 29% above the recent $143 price, and its price-to-earnings ratio below a fair level. A cheaper-looking stock can draw buyers, though the same analysis flags mixed valuation checks and cost risks.

    It explains a fresh reason investors might bid the stock up, while noting the counterweight.

  • Big consumer brands lose volume as shoppers trade down P&G's sales volume failed to grow in the latest quarter, part of a broad slide at large packaged-goods makers as shoppers switch to cheaper store brands and newer rivals. Flat volumes limit how much P&G can grow without price increases, which pressures the stock.

    It is the main new negative force and a real counterweight to the acquisition and valuation optimism.

Latest
▲3▼1

P&G buys Thorne for wellness push, but volumes stay flat

  • P&G buys Thorne for $3.8 billion P&G agreed to buy supplement maker Thorne for $3.8 billion in cash, expanding into vitamins and wellness. This gives P&G a faster-growing category and a way to reach younger shoppers, which supports the stock by adding a new source of future sales.

    The Thorne acquisition is the period's biggest new event and directly shapes P&G's growth story.

  • Beauty segment grows 11%, dividend streak hits 70 years P&G's beauty unit posted 11% sales growth and 7% organic growth on higher volumes, while the company extended its dividend increase streak to 70 years with $10 billion planned payouts. Strong beauty results and steady dividends make the stock more attractive to long-term holders.

    This shows which part of P&G is actually growing and reinforces the income appeal that supports the share price.

  • Analysts say P&G stock looks undervalued After the Thorne deal, valuation work put P&G's intrinsic value near $201 a share, about 29% above the recent $143 price, and its price-to-earnings ratio below a fair level. A cheaper-looking stock can draw buyers, though the same analysis flags mixed valuation checks and cost risks.

    It explains a fresh reason investors might bid the stock up, while noting the counterweight.

  • Big consumer brands lose volume as shoppers trade down P&G's sales volume failed to grow in the latest quarter, part of a broad slide at large packaged-goods makers as shoppers switch to cheaper store brands and newer rivals. Flat volumes limit how much P&G can grow without price increases, which pressures the stock.

    It is the main new negative force and a real counterweight to the acquisition and valuation optimism.

July 2026
▼3

P&G's costs bite: tariff and commodity headwinds hit profit and guidance

  • Tariff and commodity costs squeeze profit P&G says tariffs and higher raw material and energy costs will cut full-year profit by about $1 billion, or $0.56 a share. That directly lowers expected earnings, which is why the stock fell after results.

    This is the core new force behind the price move: real cost headwinds hitting profit.

  • Fourth-quarter revenue missed and profit fell April–June sales of $21.2 billion came in below the $21.38 billion analysts expected, and net income dropped to $3.04 billion from $3.62 billion a year earlier. The miss and weaker profit pushed shares down over 3%.

    The earnings miss is the immediate trigger for the negative price reaction.

  • Fiscal 2027 guidance points to slower growth P&G guided fiscal 2027 organic sales growth of just 1% to 3% and core EPS of $6.89 to $7.11, a slower pace than before. Weak forward guidance makes investors less willing to pay up for the stock.

    Forward guidance shapes expectations and is a key reason the stock stays under pressure.

  • Cost cuts and dividend support, but consumer strain lingers P&G is cutting 7,000 office jobs to protect margins and still returns over $15 billion to shareholders, with a 2.9% dividend yield near five-year highs. But shoppers are pushing back on price hikes and lower-income households are stretched.

    This is the real counterweight: cost savings and shareholder returns offset some weakness, but demand is soft.

▼3

P&G's costs bite: tariff and commodity headwinds hit profit and guidance

  • Tariff and commodity costs squeeze profit P&G says tariffs and higher raw material and energy costs will cut full-year profit by about $1 billion, or $0.56 a share. That directly lowers expected earnings, which is why the stock fell after results.

    This is the core new force behind the price move: real cost headwinds hitting profit.

  • Fourth-quarter revenue missed and profit fell April–June sales of $21.2 billion came in below the $21.38 billion analysts expected, and net income dropped to $3.04 billion from $3.62 billion a year earlier. The miss and weaker profit pushed shares down over 3%.

    The earnings miss is the immediate trigger for the negative price reaction.

  • Fiscal 2027 guidance points to slower growth P&G guided fiscal 2027 organic sales growth of just 1% to 3% and core EPS of $6.89 to $7.11, a slower pace than before. Weak forward guidance makes investors less willing to pay up for the stock.

    Forward guidance shapes expectations and is a key reason the stock stays under pressure.

  • Cost cuts and dividend support, but consumer strain lingers P&G is cutting 7,000 office jobs to protect margins and still returns over $15 billion to shareholders, with a 2.9% dividend yield near five-year highs. But shoppers are pushing back on price hikes and lower-income households are stretched.

    This is the real counterweight: cost savings and shareholder returns offset some weakness, but demand is soft.

Kimberly-Clark Corporation (KMB)

Q3 2026
▲2▼2

Kimberly-Clark's Kenvue bet meets China and cost setbacks

  • Kenvue acquisition adds major brands Kimberly-Clark agreed to buy Kenvue for $48.7 billion, adding Tylenol and Listerine. The deal is expected to create cost savings and more sales, expanding the company's consumer health business.

    This is the biggest new event of the quarter and a key positive driver.

  • Defensive appeal and dividend strength Kimberly-Clark's everyday products, 4.7% dividend yield, and 54-year record of raising dividends attract income investors. The stock also trades below its usual valuation, offering a margin of safety.

    This explains why investors might still favor the stock despite risks.

  • Regulatory and integration risks for Kenvue deal The Kenvue deal faces reviews in China and the EU that could delay or change it. Integrating Kenvue also brings execution challenges, and Kenvue itself struggles with inflation and tariffs pressuring its profit margins.

    These are major new risks that could hurt the deal's success and KMB's stock.

  • Outlook cut on China allegations and cost pressures Kimberly-Clark lowered its 2026 outlook after China diaper-quality claims and weaker revenue. A distribution-center fire, Middle East conflict, and higher oil prices are adding costs, weighing on results.

    This directly explains the negative revision and operational headwinds this quarter.

August 2026
▼1

Kenvue deal advances but regulatory and earnings risks weigh on KMB

  • Q2 earnings beat but 2026 outlook cut on China allegations Kimberly-Clark beat profit expectations but missed revenue and lowered its full-year outlook, citing profit pressure from false diaper quality allegations in China. The stock trades below analyst targets, and the lowered guidance signals weaker near-term earnings, which pushes the price down.

    This is the core earnings event of the period and directly explains why KMB is under pressure.

  • China antitrust review deepens, adding delay risk to Kenvue deal China's market regulator moved the $49 billion Kenvue acquisition into a phase 2 review, which could delay or change the deal. Even though shares rose slightly that day, a longer review creates uncertainty about whether the deal closes on time and on the expected terms.

    This is a new regulatory hurdle that could affect the deal's timing and value, a key driver for KMB.

  • EU approval sought for Kenvue deal, another regulatory step Kimberly-Clark asked the European Union for permission to buy Kenvue, moving the deal into another review stage. The EU filing is a request, not an approval, so the outcome and any conditions remain uncertain, keeping a cloud over the deal's completion.

    This is a new regulatory development that adds to the deal's uncertainty and is not yet in earlier reports.

  • Kenvue deal nears close but integration and financial risks remain The Kenvue combination has cleared shareholder and U.S. antitrust hurdles and is expected to close in Q4 2026, but Kenvue's recent results showed margin pressure from inflation and tariffs, and the deal still faces foreign approvals and execution risk. The benefits may not be fully realized, which could limit upside for KMB.

    This summarizes the latest status and risks of the deal, a major factor for KMB's future earnings and stock price.

Latest
▼1

Kenvue deal advances but regulatory and earnings risks weigh on KMB

  • Q2 earnings beat but 2026 outlook cut on China allegations Kimberly-Clark beat profit expectations but missed revenue and lowered its full-year outlook, citing profit pressure from false diaper quality allegations in China. The stock trades below analyst targets, and the lowered guidance signals weaker near-term earnings, which pushes the price down.

    This is the core earnings event of the period and directly explains why KMB is under pressure.

  • China antitrust review deepens, adding delay risk to Kenvue deal China's market regulator moved the $49 billion Kenvue acquisition into a phase 2 review, which could delay or change the deal. Even though shares rose slightly that day, a longer review creates uncertainty about whether the deal closes on time and on the expected terms.

    This is a new regulatory hurdle that could affect the deal's timing and value, a key driver for KMB.

  • EU approval sought for Kenvue deal, another regulatory step Kimberly-Clark asked the European Union for permission to buy Kenvue, moving the deal into another review stage. The EU filing is a request, not an approval, so the outcome and any conditions remain uncertain, keeping a cloud over the deal's completion.

    This is a new regulatory development that adds to the deal's uncertainty and is not yet in earlier reports.

  • Kenvue deal nears close but integration and financial risks remain The Kenvue combination has cleared shareholder and U.S. antitrust hurdles and is expected to close in Q4 2026, but Kenvue's recent results showed margin pressure from inflation and tariffs, and the deal still faces foreign approvals and execution risk. The benefits may not be fully realized, which could limit upside for KMB.

    This summarizes the latest status and risks of the deal, a major factor for KMB's future earnings and stock price.

July 2026
▲3▼1

Kimberly-Clark's $48.7B Kenvue Deal and Defensive Strength Drive Upside

  • Kenvue acquisition to create high-margin powerhouse Kimberly-Clark is acquiring Kenvue for $48.7 billion, adding brands like Tylenol and Listerine. The deal is expected to deliver $1.9–2.1 billion in cost synergies and $500 million in profit from revenue synergies within a few years. This expands KMB's portfolio and boosts long-term earnings power.

    The Kenvue deal is the biggest strategic move and directly affects KMB's future growth and profitability.

  • Defensive business and dividend appeal Kimberly-Clark's recession-resistant brands like Huggies and Kleenex provide steady demand. The stock offers a 4.7% dividend yield and has raised dividends for 54 straight years. It trades at about 14 times earnings, below its historical average, making it attractive to income and value investors.

    This explains why investors are willing to pay up for KMB despite market volatility.

  • Arbex joint venture sharpens focus on higher-margin products Kimberly-Clark formed a joint venture called Arbex with Suzano, offloading its lower-margin paper-towel and tissue business. This frees up resources to integrate Kenvue and focus on higher-margin personal-care products, potentially improving overall profitability.

    This strategic move supports margin expansion and the Kenvue integration.

  • Integration and cost risks could weigh on results The Kenvue deal brings execution and integration risks. Also, a California distribution center fire and Middle East conflict inflation are expected to cut second-quarter revenue by $20 million and earnings by $50 million. If oil averages $100 per barrel, additional input costs of $150–170 million could hit the second half.

    These are real near-term headwinds that could pressure KMB's stock if they worsen.

▲3▼1

Kimberly-Clark's $48.7B Kenvue Deal and Defensive Strength Drive Upside

  • Kenvue acquisition to create high-margin powerhouse Kimberly-Clark is acquiring Kenvue for $48.7 billion, adding brands like Tylenol and Listerine. The deal is expected to deliver $1.9–2.1 billion in cost synergies and $500 million in profit from revenue synergies within a few years. This expands KMB's portfolio and boosts long-term earnings power.

    The Kenvue deal is the biggest strategic move and directly affects KMB's future growth and profitability.

  • Defensive business and dividend appeal Kimberly-Clark's recession-resistant brands like Huggies and Kleenex provide steady demand. The stock offers a 4.7% dividend yield and has raised dividends for 54 straight years. It trades at about 14 times earnings, below its historical average, making it attractive to income and value investors.

    This explains why investors are willing to pay up for KMB despite market volatility.

  • Arbex joint venture sharpens focus on higher-margin products Kimberly-Clark formed a joint venture called Arbex with Suzano, offloading its lower-margin paper-towel and tissue business. This frees up resources to integrate Kenvue and focus on higher-margin personal-care products, potentially improving overall profitability.

    This strategic move supports margin expansion and the Kenvue integration.

  • Integration and cost risks could weigh on results The Kenvue deal brings execution and integration risks. Also, a California distribution center fire and Middle East conflict inflation are expected to cut second-quarter revenue by $20 million and earnings by $50 million. If oil averages $100 per barrel, additional input costs of $150–170 million could hit the second half.

    These are real near-term headwinds that could pressure KMB's stock if they worsen.

© 2026 MarketIVWhy